SYNCOMF Stock Overview
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SYNCOMF from our risk checks.
Syncom Formulations (India) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹13.80 |
| 52 Week High | ₹18.65 |
| 52 Week Low | ₹6.05 |
| Beta | 1.27 |
| 1 Month Change | 24.89% |
| 3 Month Change | -9.51% |
| 1 Year Change | 126.23% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 70.37% |
Recent News & Updates
Some Syncom Formulations (India) Limited (NSE:SYNCOMF) Shareholders Look For Exit As Shares Take 28% Pounding
Mar 21
Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With Earnings
Dec 29Recent updates
Some Syncom Formulations (India) Limited (NSE:SYNCOMF) Shareholders Look For Exit As Shares Take 28% Pounding
Mar 21Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With Earnings
Dec 29Syncom Formulations (India) Limited's (NSE:SYNCOMF) Shares Climb 26% But Its Business Is Yet to Catch Up
Dec 27Shareholder Returns
| SYNCOMF | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 10.0% | 2.3% | 2.6% |
| 1Y | 126.2% | 56.7% | 45.0% |
Return vs Industry: SYNCOMF exceeded the Indian Pharmaceuticals industry which returned 57.2% over the past year.
Return vs Market: SYNCOMF exceeded the Indian Market which returned 46.6% over the past year.
Price Volatility
| SYNCOMF volatility | |
|---|---|
| SYNCOMF Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: SYNCOMF has not had significant price volatility in the past 3 months.
Volatility Over Time: SYNCOMF's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 555 | Vijay Bankda | www.syncomformulations.com |
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations.
Syncom Formulations (India) Limited Fundamentals Summary
| SYNCOMF fundamental statistics | |
|---|---|
| Market cap | ₹12.97b |
| Earnings (TTM) | ₹263.83m |
| Revenue (TTM) | ₹2.50b |
49.2x
P/E Ratio5.2x
P/S RatioIs SYNCOMF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYNCOMF income statement (TTM) | |
|---|---|
| Revenue | ₹2.50b |
| Cost of Revenue | ₹1.52b |
| Gross Profit | ₹975.02m |
| Other Expenses | ₹711.19m |
| Earnings | ₹263.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | 0.28 |
| Gross Margin | 39.03% |
| Net Profit Margin | 10.56% |
| Debt/Equity Ratio | 29.6% |
How did SYNCOMF perform over the long term?
See historical performance and comparison